BioSpace News Archive

Nura Bio Inc., a biopharma company created to discover and develop life-changing neuroprotective drugs, today announced the publication of “Structural and Mechanistic Regulation of the Prodegenerative NAD Hydrolase SARM1” in CELL REPORTS.

Aug. 7, 2020 11:15 UTC Newly Published Physician Fee Schedules for 0356T for the Administration of Intracanalicular Inserts to Support Ongoing DEXTENZA® Launch May Financing Yields $48.3 Million in Net Proceeds DEXTENZA Net Product Revenue in Second Quarter of $1.4 million; Billable In-Market Sales Record Achieved in June

Biogen (Nasdaq: BIIB) and Eisai, Co., Ltd. (Tokyo, Japan) today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for aducanumab, an investigational treatment for Alzheimer’s disease.

Insmed Incorporated announced the granting of inducement awards to 11 new employees. In accordance with NASDAQ Listing Rule 5635, the awards were approved by Insmed’s Compensation Committee and made as a material inducement to each employee’s entry into employment with the Company.

Pfizer Inc. (NYSE: PFE) today announced a multi-year agreement with Gilead Sciences, Inc. to manufacture and supply Gilead’s investigational antiviral remdesivir, as one of multiple external manufacturing organizations supporting efforts to scale up supply of the investigational treatment for COVID-19. Under the terms of the agreement, Pfizer will provide contract manufacturing services at Pfizer’s McPherson, Kansas facility t

Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for mobile handset and wireless devices, announced it will present at the Oppenheimer 23rd Annual Virtual Technology, Internet & Communications Conference taking place August 11-12, 2020. Chairman & CEO George B. Holmes is scheduled to host a virtual fireside chat for registered event attendees, guided by

DermaSaver® Sci-Tex™ Mask Proven Nearly 92% Effective in Independent Virology Lab Test

Illumina, Inc. announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast.

Emerging Technology video presentation describing swine studies using AC5-GTM for submucosal lifting and management of gastrointestinal bleeding in endoscopic resection

Cancer Targeted Technology (CTT), a privately-held Seattle-based biotechnology company, announced that the NIH awarded CTT $1.44M on the second year of a competitive Small Business Innovation Research (SBIR) Phase IIB grant. The three year grant commenced in 2019 and totals $3.3M and this second year of funding supports the current CTT1403 clinical trial. The clinical trial, conducted at University of California, San Francis